NIH R01 · 2024
HER2-mediated delivery of cytotoxic agents in solid tumors
PROJECT SUMMARY ERBB2/HER2 is a receptor tyrosine kinase (RTK) that is amplified/overexpressed in 15-20% of breast and gastroesophageal cancers, for which anti-HER2 therapy is now standard of care. HER2 can be hyperactivated by overexpression and by mutations driving oncogenesis through receptor phosphorylation, internalization, and increased turnover. Hyperactivating HER2 mutations, possessed by thousands of patients with non-breast/non- gastric solid tumors, do not respond to classical anti-HER2 kinase therapy. Anti-HER2 antibody-drug conjugates (ADCs) offer a new treatment avenue for non-breast/non-gastric HER2-altered tumors. ADCs bind to HER2 on the cell surface, get internalized, and…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.